Signant Health在收购Ametris后于ASCP 2026参与CNS社区-动脉网

Signant Health Engages CNS Community at ASCP 2026 Following Acquisition of Ametris

CISION 等信源发布 2026-05-19 20:59



可切换为仅中文







PHILADELPHIA

费城

，

May 19, 2026

2026年5月19日

/PRNewswire/ -- Signant Health, a leading provider of evidence generation solutions for clinical trials, today announced that its scientific and medical teams will be on site at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting later this month. This engagement follows the company's recent acquisition of Ametris, a pioneer in sensor-based clinical trial data collection..

/PRNewswire/ -- Signant Health 是临床试验证据生成解决方案的领先提供商，今天宣布其科学和医学团队将在本月底出席美国临床精神药理学会 (ASCP) 年会。此次参与是在该公司近期收购传感器临床试验数据收集领域的先驱企业 Ametris 之后进行的。

Together, Signant and Ametris will meet with industry leaders, sponsors, and scientific experts throughout the conference to discuss opportunities to advance data quality, patient-centric trial design, and evidence generation.

Signant 和 Ametris 将在会议期间与行业领袖、赞助商和科学专家会面，讨论提升数据质量、以患者为中心的试验设计和证据生成的机会。

The combined organization brings together Signant's proven expertise in electronic clinical outcome assessments (eCOA), trial endpoints, and patient engagement with Ametris' innovative sensor-based data capture capabilities. This unified approach supports more continuous, objective, and high-fidelity data collection, particularly important in central nervous system (CNS) and other complex therapeutic areas..

合并后的机构将 Signant 在电子临床结果评估 (eCOA)、试验终点和患者参与方面的成熟专业知识，与 Ametris 创新的基于传感器的数据捕获能力结合在一起。这种统一的方法支持更连续、客观和高保真的数据收集，这在中枢神经系统 (CNS) 和其他复杂的治疗领域尤为重要。

'ASCP is a key forum for advancing innovation in psychopharmacology and CNS research,' said Dawie Wessels, Signant's chief medical officer. 'Our engagement this year reflects not only our continued commitment to the scientific community, but also the expanded capabilities we bring as a combined organization following the Ametris acquisition.'.

“ASCP是推动精神药理学和中枢神经系统研究创新的关键论坛，”Signant的首席医疗官Dawie Wessels表示，“我们今年的参与不仅反映了我们对科学界持续的承诺，也体现了我们在收购Ametris后作为一家联合机构所带来的扩展能力。”

As part of its ASCP activities, Signant will host a Strategic Advisory Board meeting on the final day of the conference, convening experts to discuss evolving challenges and opportunities in clinical trial measurement, digital endpoints, and real-world evidence integration.

作为其ASCP活动的一部分，Signant将在会议的最后一天举办战略咨询委员会会议，召集专家讨论临床试验测量、数字终点和真实世界证据整合方面不断变化的挑战与机遇。

Signant and Ametris representatives will also be available for pre-scheduled meetings with sponsors and partners to explore how their combined solutions can help improve trial outcomes, reduce variability, and support more robust evidence for regulatory and clinical decision-making.

Signant和Ametris的代表还将与赞助商和合作伙伴进行预先安排的会议，探讨他们联合解决方案如何帮助改善试验结果、减少变异性，并为监管和临床决策提供更有力的证据支持。

CNS trials have long relied primarily on subjective rating scales. By combining eCOA with continuous sensor-derived data, Signant and Ametris give sponsors a fuller and more objective view of what patients are experiencing between site visits, where treatment effects are often most visible yet least captured..

中枢神经系统试验长期以来主要依赖于主观评分量表。通过将电子临床结果评估（eCOA）与连续的传感器数据相结合，Signant和Ametris为申办方提供了更全面、更客观的视角，以了解患者在站点访问之间所经历的情况，而治疗效果往往在这些时段最为明显，却最难以捕捉。

To learn more about Signant and Ametris' unified approach to eCOA and sensor-based evidence generation, visit:

要了解更多关于Signant和Ametris在eCOA和基于传感器的证据生成方面的统一方法，请访问：

https://discover.signanthealth.com/ametris-unified-ecoa-sensors

About Signant Health

关于Signant Health

Signant Health is the evidence generation company, leveraging software, deep therapeutic and scientific knowledge, and operational expertise to deliver quality evidence across traditional, virtual, and hybrid trial models. For over 25 years, 600+ sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant's comprehensive eClinical solutions.

Signant Health 是一家证据生成公司，利用软件、深厚的治疗和科学知识以及运营专业知识，在传统、虚拟和混合试验模型中提供高质量的证据。25 年多来，600 多家各种规模的赞助商和合同研究组织（CRO）——包括全球前 20 大制药公司——都信赖 Signant 的全面电子临床解决方案。

Our clinical outcome assessments (eCOA, clinician ratings, cognitive testing) and wearable digital health technologies powered by Ametris provide the industry's most comprehensive evidence generation capabilities, alongside EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at .

我们的临床结果评估（eCOA、临床医生评分、认知测试）和由Ametris驱动的可穿戴数字健康技术，提供了行业内最全面的证据生成能力，同时还包括EDC、eConsent、RTSM、供应链管理以及数据质量分析。欲了解更多信息，请访问。

www.signanthealth.com

。

Contact:

联系：

Heather Bilinski

贺瑟·比利恩斯基

[email protected]

+1 610.400.4141

Logo -

标志 -

https://mma.prnewswire.com/media/1202052/5976350/Signant_Health_Logo.jpg